When we wrote about Pfizer’s decision to pay $2.3 billion in fines to settle allegations that it illegally marketed several drugs for off-label use, we heard a lot of talk about the tough conditions in the corporate integrity agreement Pfizer signed as part of the deal.
Today, our colleagues at Corporate Counsel focus on one part of that agreement that forces Pfizer’s general counsel to give up its role as overseer of the company’s compliance program. Under the terms of the agreement, which Pfizer signed with the U.S. Department of Health and Human Services, the company’s chief compliance officer will skip over the GC’s office and report directly to Pfizer’s chief executive, according to the story.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]